Verde Media Biotech Division Advances On Alternative Proprietary Technology For Scaled Cannabinoid Production
Verde Biotech Division has developed a new, more cost-effective method for developing medicinal CBD oil and is moving forward with a pilot facility for massive scale-up.
Los Angeles, CA, August 12, 2014 (Newswire.com) - Verde Media Group Inc. (OTC:VMGI), through its Verde Media Biotechnology Division (VMBD) announces plans for genetically modifying a proprietary strain of yeast to produce cannabis-identical phytocannabinoids, including D9 tetrahydrocannabinol (THC) and cannabidiol (CBD). The VMBD team will use the tool of metabolic engineering that allows transfer of Cannabis genetic pathways in yeast, representing an alternative route to produce cannabinoids, at an affordable and scalable manner.
CBD oils are a natural non-psychoactive component of the marijuana plant (Cannabis) and offer unique therapeutic oils for patients with medical conditions such as cancer, anorexia, AIDS, chronic pain, spasticity, glaucoma, arthritis, and migraines. By utilizing sugars to grow genetically engineered yeast to produce CBD, they can achieve economical scale-up, necessary for large mass-production. This alternative route for CBD production is less intensive on power consumption compared to a greenhouse method of producing Cannabis. Furthermore, the technology process is green and uses feed stocks that are renewable and can be replicated globally using a proprietary fermentation process. The technology developed by the VMBD team will be licensed in a health and wellness industry that represents a growing $5 billion industry.
This new development will give the VMBD division another revenue stream developing and producing high value bio-products utilizing proprietary technologies with low risk and a scale-up utilizing low cost feedstock. After successful production at demonstration scale, such technologies and products will be licensed and sold to third parties globally.
"We are very excited in developing an alternative and microbial platform to produce cannabinoids in an economical manner that offers a unique opportunity to mass-produce medically important phytocannabinoids."
Dr. Abidi, Ph.D. CEO of VMBD stated, “We are very excited in developing an alternative and microbial platform to produce cannabinoids in an economical manner that offers a unique opportunity to mass-produce medically important phytocannabinoids.”
About Verde Media Group Inc.
Verde Media Group Inc. is a publicly traded company listed on the OTC Markets trading under the stock symbol: VMGI. Verde Media Group Inc. The company consists of three divisions:
Agency Division- The innovative Agency division services- public relations, marketing, and transaction functions for corporate clientele.
BioTech Division- The Biotech Division manages a portfolio of biotech companies and the VMBD division undertakes the business of developing and producing high value bio-products from renewable biomass. The focus and criterion is to develop proprietary microbial technologies with low risk scale-up methods employing low cost feedstock.
Entertainment Division- The company operates a managed media company with production, distribution, development, and acquisition functions for film and television.
DISCLAIMER: CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS
The results described herein cannot be guaranteed. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release other than statements of historical fact are "forward-looking statements" that are based on current expectations and assumptions.
CONTACT: Verde Media Group, Inc., 310-954-9160
Source: Verde Media Group, Inc.